Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Express Scripts
AstraZeneca
Medtronic

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR OLYSIO


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Olysio

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02118597 ↗ An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients Terminated Hoffmann-La Roche 2014-05-01 This prospective, national, multicenter, non-interventional study examined the use of triple combination therapy with boceprevir, pegylated interferon (peginterferon) alfa-2a and ribavirin in re-treating participants with genotype 1 chronic hepatitis C (CHC) infection. Dosing and treatment duration were at the discretion of the investigator in accordance with local clinical practice and local labeling. Participants were to be observed for the duration of their triple combination therapy and for up to 24 weeks thereafter.
NCT02168361 ↗ The SIM-SOF Trial for Hepatitis C Completed Center For Hepatitis C, Atlanta, GA Phase 4 2013-12-01 Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label combination of simeprevir+ sofosbuvir without Ribavirin.
NCT02206932 ↗ A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C Withdrawn Janssen Scientific Affairs, LLC Phase 4 2014-08-01 This is a study of the safety and effectiveness of the hepatitis C medications sofosbuvir and simeprevir in patients who have both the HIV and hepatitis C (HCV) viruses.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Olysio

Condition Name

Condition Name for Olysio
Intervention Trials
Chronic Hepatitis C 2
Hepatitis C 2
Hepatitis C, Chronic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Olysio
Intervention Trials
Hepatitis C 7
Hepatitis 6
Hepatitis C, Chronic 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Olysio

Trials by Country

Trials by Country for Olysio
Location Trials
United States 5
Hungary 1
Egypt 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Olysio
Location Trials
California 2
Connecticut 1
Colorado 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Olysio

Clinical Trial Phase

Clinical Trial Phase for Olysio
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Olysio
Clinical Trial Phase Trials
Completed 3
Withdrawn 2
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Olysio

Sponsor Name

Sponsor Name for Olysio
Sponsor Trials
Janssen Scientific Affairs, LLC 3
Stanford University 1
Achillion Pharmaceuticals 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Olysio
Sponsor Trials
Industry 7
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Colorcon
Mallinckrodt
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.